Related Experiment Videos
Somatostatin receptor expression in multiple endocrine neoplasia and in von Hippel-Lindau disease
S W Lamberts1, L J Hofland, A J Lely
1Department of Medicine, Erasmus University Rotterdam, The Netherlands. lamberts@inw3.azr.nl
Abstract:
Somatostatin receptors are expressed on the majority of neuroendocrine tumours. The presence of these receptors is clinically useful. First, long-term treatment with somatostatin analogues controls hormonal hypersecretion, which controls flushing attacks, watery diarrhoea, hypoglycaemia and electrolyte disorders in patients with carcinoids and islet cell tumours. Secondly, somatostatin receptor imaging is used to localize primary neuroendocrine tumours and to visualize the spread of the disease. Thirdly internalization of somatostatin receptors by primary neuroendocrine tumours opens the possibility of carrying out radio- and chemotherapy with somatostatin analogues coupled to beta-emitting radionuclides and chemotherapeutic drugs. The presence and role of somatostatin receptors on the tumours which occur in multiple endocrine neoplasia and von Hippel-Lindau disease are discussed.
Insights
Somatostatin receptors on neuroendocrine tumors aid in controlling hormonal symptoms and disease spread. They also enable targeted therapies using somatostatin analogues for improved patient outcomes.
Area of Science:
- Endocrinology
- Oncology
- Nuclear Medicine
Background:
- Somatostatin receptors are prevalent in most neuroendocrine tumors (NETs).
- These receptors play a crucial role in the clinical management of NETs.
Purpose of the Study:
- To review the clinical utility of somatostatin receptors in neuroendocrine tumors.
- To discuss their role in treatment, imaging, and targeted drug delivery.
Main Methods:
- Literature review focusing on somatostatin receptor expression and function in NETs.
- Analysis of clinical applications including somatostatin analogue therapy and receptor imaging.
Main Results:
- Somatostatin analogues effectively manage hormonal hypersecretion in NETs.
- Somatostatin receptor imaging facilitates tumor localization and metastasis detection.
- Receptor internalization offers potential for targeted radio- and chemotherapy.
Conclusions:
- Somatostatin receptors are vital diagnostic and therapeutic targets in neuroendocrine tumors.
- Their presence facilitates symptom control, disease staging, and novel treatment strategies.
- The role of these receptors in multiple endocrine neoplasia and von Hippel-Lindau disease warrants further investigation.